Nanoparticles for theranostics, combining imaging and therapy
NH TherAguix is a biotechnology company developing a technology platform for intravenously administered radiosensitizing nanoparticles, the result of ten years of international academic research.
Currently in phase 2 clinical evaluation in cancer patients, its drug candidate AGuIX® , whose potential efficacy is based on a nanometric structure, allows its administration by intravenous injection and the combination of the three essential assets to fight tumors: targeting, imaging and treatment.
The AGuIX technology is therefore part of the theranostics concept, which corresponds to a combination of therapy (radiosensitizing effect) and diagnosis (visible in MRI), and more broadly in the personalized medicine of tomorrow.
Géraldine LE DUC.
Increase the effectiveness of radiotherapy treatments for cancers without destroying healthy cells.